SCHEMBL30454061

SCHEMBL30454061

CCOC(=O)CNC(=O)c1ncc(-c2cnn(-c3ccccc3)c2F)c(C)c1OCOCCOC

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.43
HPGD P15428 4/20 0.42
RAB9A P51151 4/20 0.41
GAA P10253 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
HSD17B10 Q99714 2/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
EGLN1 Q9GZT9 1/20 0.35
MAPT P10636 2/20 0.35
NPC1 O15118 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
MAPK1 P28482 1/20 0.35
RXFP1 Q9HBX9 1/20 0.34
HTT P42858 2/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30452382 0.75 SMN1; SMN2 (0.37) ALDH1A1HPGDRAB9AGAAL3MBTL1
SCHEMBL24257722 0.75 HPGD (0.48) ALDH1A1HPGDRAB9AGAAL3MBTL1
SCHEMBL24257825 0.74 GAA (0.41) ALDH1A1HPGDRAB9AGAAPOLB
SCHEMBL24257476 0.73 EGLN1 (0.45) ALDH1A1LMNAEGLN1
SCHEMBL26260146 0.73 RAB9A (0.43) ALDH1A1HPGDRAB9AGAAL3MBTL1
SCHEMBL24257745 0.70 GRM4 (0.42) ALDH1A1HPGDRAB9AGAAL3MBTL1
SCHEMBL24257826 0.70 KDM4E (0.41) ALDH1A1HPGDRAB9AGAAPOLB
SCHEMBL26260144 0.69 ALDH1A1 (0.41) ALDH1A1HPGDRAB9AGAAL3MBTL1
SCHEMBL26260138 0.69 SMN1; SMN2 (0.43) ALDH1A1HPGDRAB9AGAATP53
SCHEMBL24257801 0.69 RAB9A (0.42) ALDH1A1HPGDRAB9AGAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 ALDH1A1 1362/4885HPGD 109/4885RAB9A 739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.